Seeking Alpha

Goldman Sachs adds Gilead Sciences (GILD) to its Conviction Buy list, calling its acquisition...

Goldman Sachs adds Gilead Sciences (GILD) to its Conviction Buy list, calling its acquisition strategy "transformational." Analysts with the firm set a $46 price target on shares - hailing the mega-acquisition of Pharmasset (VRUS) as a move that changes the stock to a value story from a growth story.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs